@article{5afb69bfd4264dc8a60ca41148ed79d9,
title = "Permissive omicron breakthrough infections in individuals with binding or neutralizing antibodies to ancestral SARS-CoV-2",
abstract = "Background: Breakthrough infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) has occurred in populations with high vaccination rates. Methods: In a longitudinal cohort study, pre-breakthrough infection sera for Omicron breakthroughs (n = 12) were analyzed. Assays utilized include a laboratory-developed solid phase binding assay to recombinant spike protein, a commercial assay to the S1 domain of the spike protein calibrated to the World Health Organization (WHO) standard, and a commercial solid-phase surrogate neutralizing activity (SNA) assay. All assays employed spike protein preparations based on sequences from the Wuhan-Hu-1 strain. Results: Pre-breakthrough binding antibody titers ranged from 1:800 to 1:51,200 for the laboratory-developed binding assay, which correlated well and agreed quantitatively with the commercial spike S1 domain WHO calibrated assay. SNA was detected in 10/12 (83%) samples. Conclusions: Neither high binding titers nor SNA were markers of protection from Omicron infection/re-infection.",
keywords = "Binding antibodies, Breakthrough, Neutralizing antibodies, Omicron, SARS-CoV-2",
author = "Erin Williams and Jordan Colson and Ranjini Valiathan and Carre{\~n}o, {Juan Manuel} and Florian Krammer and Michael Hoffer and Suresh Pallikkuth and Savita Pahwa and David Andrews",
note = "Funding Information: As ever, we are grateful to our research participants for their samples, time, and interest in this work. At the University of Miami Miller School of Medicine, we thank Aria Nawab, Daniel Muniz, Felipe Echeverri Tribin, Margaret Roach, Elizabeth Varghese, and the entire phlebotomy team at the Clinical Translational Research Site. We would also like to thank the SARS-CoV-2 serology team at the Icahn School of Medicine at Mount Sinai, including Dominika Bielak and Gagandeep Singh. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Funding Information: This work was partly funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051 as part of the PARIS/SPARTA studies. Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2022",
month = sep,
day = "29",
doi = "10.1016/j.vaccine.2022.08.058",
language = "English",
volume = "40",
pages = "5868--5872",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "41",
}